Cerulean Pharma Inc. (NASDAQ:DARE) Lifted to “Hold” at ValuEngine

ValuEngine upgraded shares of Cerulean Pharma Inc. (NASDAQ:DARE) from a sell rating to a hold rating in a report published on Saturday, July 22nd.

Shares of Cerulean Pharma (NASDAQ:DARE) traded down 1.43% during midday trading on Friday, reaching $2.76. 41,267 shares of the company traded hands. Cerulean Pharma has a 12 month low of $2.63 and a 12 month high of $35.80. The company has a 50 day moving average of $4.87 and a 200 day moving average of $7.60. The firm’s market capitalization is $8.01 million.

TRADEMARK VIOLATION WARNING: This piece was published by BNB Daily and is the property of of BNB Daily. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.baseball-news-blog.com/2017/08/19/cerulean-pharma-inc-nasdaqdare-lifted-to-hold-at-valuengine-updated-updated-updated.html.

About Cerulean Pharma

Dare Bioscience, Inc, formerly Cerulean Pharma Inc, is a healthcare company. The Company is focused on the development and commercialization of products in women’s reproductive health. Its lead product candidate is Ovaprene, a clinical stage, non-hormonal contraceptive ring. The Company is developing Ovaprene to provide protection over multiple weeks of use and require no intervention at the time of intercourse.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Cerulean Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerulean Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply